Anti-Human MUC1 Recombinant Antibody Fab Fragment (Clivatuzumab Tetraxetan) (CAT#: TAB-037-F(E))

Recombinant antibody Fab to MUC1. Yttrium (90Y) clivatuzumab tetraxetan (trade name hPAM4-Cide) is a humanized monoclonal antibody designed for the treatment of pancreatic cancer. The antibody itself, clivatuzumab, is conjugated with tetraxetan, a chelator for yttrium-90, a radioisotope which destroys the tumour cells.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
IF

Figure 1 Co-localization of PAM4 antigen with MUC5AC by immunofluorescence staining.

Figure 1 Co-localization of PAM4 antigen with MUC5AC by immunofluorescence staining.

(A) Mucin-expressing cell lines were stained with DAPI, hPAM4, and anti-MUC5AC (2-12M1 for Capan-1 and BxPC-3; 2-11M1 for HT-29 and MCF-7), then examined by immunofluorescence microcopy. (B) BxPC-3 and HT-29 cells were stained with DAPI, hPAM4, and α-MUC1. PAM4 antigen was shown to co-localize with MUC5AC, not MUC1.

Liu, D., Chang, C. H., Gold, D. V., & Goldenberg, D. M. (2015). Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: A promising biomarker and therapeutic target for pancreatic cancer. Oncotarget, 6(6), 4274.

IF

Figure 2 Co-knockdown of PAM4 antigen and MUC5AC by MUC5AC-specific siRNA.

Figure 2 Co-knockdown of PAM4 antigen and MUC5AC by MUC5AC-specific siRNA.

(A) CFPAC-1 cells were treated with a MUC5AC-specific siRNA, followed by staining with DAPI, hPAM4, and 2-11M1. (B) CFPAC-1 cells were treated with a MUC5ACspecific siRNA, followed by staining with DAPI, hPAM4, α-MUC1. Untreated Cells or cells treated with only the transfection agent (mock) served as controls. Cells treated with MUC5AC-specific siRNA lost the binding to anti-MUC5AC and hPAM4 concurrently, with little effect on the binding to anti-MUC1.

Liu, D., Chang, C. H., Gold, D. V., & Goldenberg, D. M. (2015). Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: A promising biomarker and therapeutic target for pancreatic cancer. Oncotarget, 6(6), 4274.

Activ

Figure 3 Immunoreactivity of fractions eluted from Sepharose CL-2B.

Figure 3 Immunoreactivity of fractions eluted from Sepharose CL-2B.

(A) Capan-1 cell culture supernatant was separated on a Sepharose CL2B column with the eluted fractions analyzed by hPAM4 and α-MUC1. (B) The void-volume (Vo) fractions of Capan-1 reacted positively with three anti-MUC5AC antibodies (45M1, 1-13M1 and H-160), but not with 2Q445, which recognizes the unglycosylated tandem repeat region of MUC5AC. (C) The Capan-1 void-volume peak, following capture by 2-11M1, could be detected directly by HRP-hPAM4, or indirectly by biotin-45M1 plus SA-HRP.

Liu, D., Chang, C. H., Gold, D. V., & Goldenberg, D. M. (2015). Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: A promising biomarker and therapeutic target for pancreatic cancer. Oncotarget, 6(6), 4274.

WB

Figure 4 Agarose gel electrophoresis.

Figure 4 Agarose gel electrophoresis.

(A) The Capan-1 void-volume peak displayed the characteristic banding pattern of MUC5AC as revealed by Western blot analysis with hPAM4, 45M1, and MAN-5ACI. In the left panel, samples in the lanes marked as 1, 1/2, 1/4, and 1/8 were tested undiluted, 2-, 4- and 8-fold diluted, respectively. In the far right panel, the monomeric and dimeric MUC5AC were indicated as M and D, respectively. (B) The serum from a pancreatic cancer patient (PS) tested positive for hPAM4-reactive substance was differentially detected by hPAM4 and three anti-MUC5AC antibodies (2-11M1, 45M1, and H-160). The Capan-1 void-volume peak (Vo) and normal serum sample (NS) were included as controls.

Liu, D., Chang, C. H., Gold, D. V., & Goldenberg, D. M. (2015). Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: A promising biomarker and therapeutic target for pancreatic cancer. Oncotarget, 6(6), 4274.

WB

Figure 5 Mapping the PAM4-reactive epitope on human MUC5AC.

Figure 5 Mapping the PAM4-reactive epitope on human MUC5AC.

(A) Schematic diagram of different MUC5AC recombinant fragments (a–h) generated in PANC-1 cells for mapping PAM4 epitope; Numbers are AA positions in the MUC5AC protein sequence (UniProtKB/Swiss-Prot: P98088). (B to E) Western blot of various MUC5AC recombinant fragments by hPAM4, anti-MUC5AC, or antiGFP antibodies, as indicated. See text for details. Lane m indicates samples from untransfected cells.

Liu, D., Chang, C. H., Gold, D. V., & Goldenberg, D. M. (2015). Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: A promising biomarker and therapeutic target for pancreatic cancer. Oncotarget, 6(6), 4274.

ELISA

Figure 6 Reactivity of several anti-mucin MAbs with a high molecular weight mucin containing fraction (CPM1) isolated from the Capan-1 human pancreatic adenocarcinoma.

Figure 6 Reactivity of several anti-mucin MAbs with a high molecular weight mucin containing fraction (CPM1) isolated from the Capan-1 human pancreatic adenocarcinoma.

MAbs are identified by clone name with reactive species of mucin indicated by horizontal bars beneath MAb clone names (MUC1, etc.). In addition to PAM4, substantial reactions were observed for anti-MUC1, -MUC5AC, and -CEACAM6 antibodies. All MAbs were employed at a concentration of 10 μg/mL.

Gold, D. V., Newsome, G., Liu, D., & Goldenberg, D. M. (2013). Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin. Molecular cancer, 12(1), 143.

ELISA

Figure 7 Reaction of several anti-mucin MAbs with PAM4-captured antigen.

Figure 7 Reaction of several anti-mucin MAbs with PAM4-captured antigen.

Mucin antigens were captured on hPAM4 coated plates, and then probed with several murine anti-mucin MAbs for reaction signal. Both anti-MUC5AC MAbs (2-11 M1 and 45 M1) bound to the hPAM4-captured mucin, whereas the anti-MUC1 MAbs (MA5 and KC4) did not bind. The homologous hPAM4/mPAM4, capture/probe immunoassay gave no signal, suggesting the density of PAM4 epitopes within the mucin may be low, possibly only a single site. A rabbit polyclonal anti-CPM1 IgG was used as a positive control for reaction with hPAM4-captured antigen.

Gold, D. V., Newsome, G., Liu, D., & Goldenberg, D. M. (2013). Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin. Molecular cancer, 12(1), 143.

Inhib

Figure 8 Inhibition of hPAM4/antigen binding reaction by murine anti-mucin MAbs.

Figure 8 Inhibition of hPAM4/antigen binding reaction by murine anti-mucin MAbs.

A) Anti-mucin mMAbs (purified IgG) were added to CPM1-coated plates as potential inhibitors prior to addition of hPAM4. mPAM4 provided almost complete inhibition of the reaction between hPAM4 and antigen with the 45 M1 anti-MUC5AC providing limited inhibitory effect (ICmax = 25.5%). Neither 2-11 M1, anti-MUC5AC nor MA5 and KC4, anti-MUC1 MAbs were able to inhibit the specific hPAM4/antigen reaction. B) A similar inhibition study was performed with several anti-MUC5AC MAbs obtained as ascites fluids. MAbs 21 M1, 62 M1, and 463 M1, anti-MUC5AC provided substantial inhibitory effect, similar to that observed with mPAM4 IgG self-inhibition.

Gold, D. V., Newsome, G., Liu, D., & Goldenberg, D. M. (2013). Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin. Molecular cancer, 12(1), 143.


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Mouse
  • Derivation
  • Humanized (from mouse)
  • Type
  • Fab - G1 - kappa
  • Specificity
  • Tested positive against native human antigen.
  • Species Reactivity
  • Human
  • Applications
  • Neut, ELISA, IF, IP, FuncS, FC, IHC, Activ, WB, Inhib
  • Trade name
  • hpam4-cide
  • CAS
  • 943976-23-6
  • Generic Name
  • Clivatuzumab tetraxetan
  • MW
  • 145,723.71 g/mol

Product Property

  • Purity
  • >95.0% as determined by analysis by RP-HPLC.
  • Storage
  • At -20°C for one year.

Applications

  • Application Notes
  • The MUC1 antibody has been reported in applications of Neut, ELISA, IF, IP, FuncS, FC, IHC, Activ, WB, Inhib.

Target

  • Alternative Names
  • Clivatuzumab tetraxetan;hpam4-cide;943976-23-6;hPAM4-Cide;Yttrium (90Y) clivatuzumab tetraxetan;MUC1;mucin 1, cell surface associated;mucin 1, transmembrane , PUM;mucin-1;CD227;PEM;episialin;DF3 antigen;H23 antigen;krebs von den Lungen-6;mucin 1, transmem

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "MUC1"

Humanized Antibody

CAT Product Name Application Type
TAB-166 Humanized Anti-MUC1 Recombinant Antibody (clone Cantuzumab) IP, IF, FuncS, FC, Neut, ELISA, ICC Humanized (from mouse) IgG1, κ
TAB-413MZ Human Anti-MUC1 Recombinant Antibody (TAB-413MZ) ELISA Humanized IgG
TAB-425MZ Anti-Human MUC1 Recombinant Antibody (huDMB5F3) ELISA, FC, FuncS, ICC Humanized antibody
TAB-430MZ Anti-Human MUC1 Recombinant Antibody (BLC595) ELISA, FC Humanized antibody
TAB-026ML Anti-Human MUC1 Recombinant Antibody (Gatipotuzumab) ELISA, IHC, FC, IP, IF, FuncS IgG1, κ

Immunotoxin

CAT Product Name Application Type
AGTO-L036E anti-MUC1 immunotoxin C242 (Fab)-PE Cytotoxicity assay, Functional assay
AGTO-L064E anti-MUC1 immunotoxin H23 (scFv)-PE Cytotoxicity assay, Functional assay

Fab Glycosylation

CAT Product Name Application Type
Gly-012LC Recombinant Anti-Human MUC1 Antibody (Fab glycosylation/Sialylated) ELISA, FC, IHC Humanized antibody
Gly-120LC Recombinant Anti-Human MUC1 Antibody (Fab glycosylation) ELISA Mouse antibody

Sialylated IgG Glycan

CAT Product Name Application Type
Gly-012LC-1 Recombinant Anti-Human MUC1 Antibody (Fab glycosylation/Sialylated) ELISA, FC, IHC Humanized antibody

Fc Glycosylation

CAT Product Name Application Type
Gly-109LC Recombinant Anti-Human MUC1 Antibody (Fc glycosylation) ELISA Human antibody

Deglycosylated Antibody (Non-glycosylated IgGs)

Chicken IgY Antibody

CAT Product Name Application Type
BRD-0379MZ Chicken Anti-MUC1 Polyclonal IgY IHC, WB Chicken antibody

Rabbit Monoclonal Antibody

CAT Product Name Application Type
MOR-2320 Hi-Affi™ Recombinant Rabbit Anti-MUC1 Monoclonal Antibody (DS2320AB) IHC-P, IHC-Fr IgG

Recombinant Antibody

CAT Product Name Application Type
MOB-124CQ Mouse Anti-Human MUC1 Antibody IHC, IF Mouse IgG1, κ
FAMAB-0225YC Mouse Anti-MUC1 Recombinant Antibody (clone MUSE11) IHC Mouse IgG1
ZG-0962F Mouse Anti-MUC1 Recombinant Antibody (clone 139H2) EM, ELISA, FC, IF, IHC-Fr, IP, WB Mouse IgG1
ZG-0965F Mouse Anti-MUC1 Recombinant Antibody (clone 175C5) EM, ELISA, FC, IF, IHC-Fr, IP, WB Mouse IgG1
ZG-0972F Mouse Anti-MUC1 Recombinant Antibody (clone 214D4) FC, IHC-Fr, IHC-P Mouse IgG1

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-H56 Afuco™ Anti-MUC1 ADCC Recombinant Antibody (Pemtumomab), ADCC Enhanced FuncS, IF, Neut, ELISA, FC ADCC enhanced antibody
AFC-TAB-H65 Afuco™ Anti-MUC1 ADCC Recombinant Antibody (Sontuzumab), ADCC Enhanced ELISA, FC, IP, FuncS, IF ADCC enhanced antibody
AFC-TAB-026ML Afuco™ Anti-MUC1 ADCC Recombinant Antibody (Gatipotuzumab), ADCC Enhanced ELISA, IHC, FC, IP, IF, FuncS ADCC enhanced antibody
AFC-TAB-166 Afuco™ Anti-MUC1 ADCC Recombinant Antibody (Cantuzumab), ADCC Enhanced IP, IF, FuncS, FC, Neut, ELISA ADCC enhanced antibody
AFC-TAB-H77 Afuco™ Human Anti-MUC1 Recombinant Antibody, ADCC Enhanced (AFC-TAB-H77) ELISA, FC, IP, FuncS, IF IgG1, κ

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-037-F(E). Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare